References
- Roupret M, Zigeuner R, Palou J, Boehle A, Kaasinen E, Sylvester R, et al. European guidelines for the diagnosis and management of upper urinary tract urothelial cell carcinomas: 2011 update. Eur Urol 2011;59:584-94. https://doi.org/10.1016/j.eururo.2010.12.042
- Tawfiek ER, Bagley DH. Upper-tract transitional cell carcinoma. Urology 1997;50:321-9. https://doi.org/10.1016/S0090-4295(97)00230-6
- Seymour JE, Malin JM Jr, Pierce JM Jr. Late metastases of a superficial transitional cell carcinoma of the bladder: report of a case. J Urol 1972;108:277-8.
- Dougherty DW, Gonsorcik VK, Harpster LE, Trussell JC, Drabick JJ. Superficial bladder cancer metastatic to the lungs: two case reports and review of the literature. Urology 2009;73:210.e3-5.
- Hall MC, Womack S, Sagalowsky AI, Carmody T, Erickstad MD, Roehrborn CG. Prognostic factors, recurrence, and survival in transitional cell carcinoma of the upper urinary tract: a 30-year experience in 252 patients. Urology 1998;52:594-601 https://doi.org/10.1016/S0090-4295(98)00295-7
- Sengelov L, Kamby C, von der Maase H. Pattern of metastases in relation to characteristics of primary tumor and treatment in patients with disseminated urothelial carcinoma. J Urol 1996;155:111-4.
- Munoz JJ, Ellison LM. Upper tract urothelial neoplasms: incidence and survival during the last 2 decades. J Urol 2000;164: 1523-5. https://doi.org/10.1016/S0022-5347(05)67019-X
- Galsky MD, Hahn NM, Rosenberg J, Sonpavde G, Hutson T, Oh WK, et al. Treatment of patients with metastatic urothelial cancer "unfit" for Cisplatin-based chemotherapy. J Clin Oncol 2011;29:2432-8. https://doi.org/10.1200/JCO.2011.34.8433
- Amin MB. Histological variants of urothelial carcinoma: diagnostic, therapeutic and prognostic implications. Mod Pathol 2009;22 Suppl 2:S96-118. https://doi.org/10.1038/modpathol.2009.26
- Nigwekar P, Amin MB. The many faces of urothelial carcinoma: an update with an emphasis on recently described variants. Adv Anat Pathol 2008;15:218-33. https://doi.org/10.1097/PAP.0b013e31817d79b9
- Kaufmann O, Fietze E, Mengs J, Dietel M. Value of p63 and cytokeratin 5/6 as immunohistochemical markers for the differential diagnosis of poorly differentiated and undifferentiated carcinomas. Am J Clin Pathol 2001;116:823-30. https://doi.org/10.1309/21TW-2NDG-JRK4-PFJX
- Kunju LP, Mehra R, Snyder M, Shah RB. Prostate-specific antigen, high-molecular-weight cytokeratin (clone 34betaE12), and/or p63: an optimal immunohistochemical panel to distinguish poorly differentiated prostate adenocarcinoma from urothelial carcinoma. Am J Clin Pathol 2006;125:675-81. https://doi.org/10.1309/V1RY91NKX5ARW2Q5
- Mukhopadhyay S, Katzenstein AL. Subclassification of nonsmall cell lung carcinomas lacking morphologic differentiation on biopsy specimens: Utility of an immunohistochemical panel containing TTF-1, napsin A, p63, and CK5/6. Am J Surg Pathol 2011;35:15-25. https://doi.org/10.1097/PAS.0b013e3182036d05
- Aguirre-Ghiso JA. Models, mechanisms and clinical evidence for cancer dormancy. Nat Rev Cancer 2007;7:834-46. https://doi.org/10.1038/nrc2256
Cited by
- Pulmonary metastasis from urothelial carcinoma of the upper urinary tract 29 years after nephrectomy vol.3, pp.None, 2013, https://doi.org/10.1186/s40792-017-0293-3